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ABSTRACT 
 
Background: The numbers of individuals age 50 and over who maintain active lifestyles 
is growing.  Many of these individuals travel to or live at, higher altitudes, to pursue 
outdoor activities or travel to higher altitudes for business.  The use of anticoagulant 
therapy has continued to increase over the past two decades among individuals 50 and 
over.  Warfarin is effective but requires a narrow therapeutic range based on the 
International Normalized Ratio (INR).  Clinicians have concerns as to whether, 
ascending to higher altitudes, affects coagulation parameters and INR in warfarin 
patients. 
Methods: A comprehensive search was conducted using Medline, CINAHL, Web of 
Science, Pubmed, and EBMR multifile.  Three studies were chosen based on relevance 
to the topic.  Each study was evaluated using GRADE criteria. 
Results: Results from all three studies show that increase in altitude changes 
coagulation parameters indicating of a hypercoagulable state.  A retrospective chart 
review determined that warfarin patients traveling to an altitude of 2400m had a 
significantly increased risk of subtherapeutic INR.  An observational study on a high 
altitude expedition showed changes in coagulation parameters resulting in 
hypercoagulation.  A cohort study of subjects ascending to high altitude also showed 
tendency towards a thrombotic state, especially an increase in fibrinolysis inhibitors, 
platelets and hemoglobin. 
Conclusion: The studies show that altitude can change coagulation parameters which 
contribute to a hypercoagulable state and could decrease INRs of warfarinized patients 
in whom ascending to altitude increases the risk of thrombosis.  The body of evidence 
was rated as low according to GRADE guidelines. 
Keywords:  Altitude, Coagulation, Anticoagulation, Warfarin, International Normalized 
Ratio (INR), Hypobaric, Hypoxia. 
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INTRODUCTION 
Background 
In the United States, the expected population of individuals age 50 and older is 
estimated to rise to 100 million by 2012 (Pirkl, 2009).  Baby Boomers (age 46-64) have 
continued to live an active lifestyle, refusing to settle for idleness.  These individuals 
frequently travel all over the world pursuing outdoor recreation and adventure.  Many 
travel to high elevations to visit national parks, ski in our nation’s mountain resorts, and 
vacation in high mountain towns to golf, hike, bike and fish.  A study in Nepal identified 
20% of visitors applying for travel visas as 50 or older and one third of whom were 
planning to take part in mountain trekking (Shlim & Houstan, 1989).  Some pursue more 
extreme activities throughout their 50s and later years, like high altitude mountaineering.  
The numbers of mountaineers over the age of 50 climbing Mt. McKinley (6194m) has 
increased since the National Park Service began standardizing expedition records in 
1990 (McIntosh, Devitt, Rodway, Dow, & Grissom, 2010).  The standard expedition 
route begins after a flight from sea level to base camp at 2190m.  The number of 
climbers on Mt. Everest (8,848m), in 2000-2005, over the age of 59 quadrupled (Huey, 
Salisbury, Wang, & Mao, 2007).  Not all of these Boomers or “Zoomers” have time for 
adventurous pursuits but many continue to work and travel for business to higher 
altitude locations (Pirkl, 2009).  A large number live at higher altitudes in the U.S. and 
travel to lower elevations during the winter and return in the spring. 
Ascent to higher altitudes causes hypobaric hypoxia and is known to cause 
physiologic changes in humans such as decreases in tissue oxygenation and 
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sympathetic compensatory changes; elevated systemic blood pressure; arrhythmias 
and vasoconstriction (Auerbach, 2007).    Hyper viscous blood from hypobaric hypoxic 
altitude induced polycythemia could lead to a thrombotic state (Vij, 2009).  There have 
been documented cases of healthy mountaineers suffering from altitude induced 
thrombosis and death (Bartsch, 2006).    Pichler-Hefti et al. (2010), showed an increase 
in procoagulatory state with increased altitude.  The increase in procoagulants has been 
seen without an equal counter response of fibrinolysis, thus creating a hypercoagulable 
state.   The negative effects of high altitudes are worsened by comorbidities.  Burtscher 
(2007) showed the risk of sudden cardiac death of hikers at altitude, increased 
significantly with history of prior myocardial infarction, diabetes, known coronary artery 
disease and hypercholesterolemia.     
An increasing number of individuals 50 years and older remain active while 
successfully managing comorbidities such as hypertension, diabetes and 
hyperlipidemia.  In addition to these conditions, some suffer from clotting disorders; 
history of deep venous thrombosis (DVT) or pulmonary embolus; atrial fibrillation (AF); 
valvular stenosis; history of stroke or transient ischemic attack (TIA); have a pacemaker; 
or have an artificial heart valve. These conditions usually require chronic, long-term or 
lifelong anticoagulant therapy to prevent either an initial or recurring thromboembolic 
event.   
 Warfarin, a vitamin K antagonist (VKA), has been successfully used for 
anticoagulant therapy for over forty years and is the most commonly prescribed VKA for 
long term anticoagulation (Fauci et al., 2008).  Warfarin use has seen a threefold 
increase in the past two decades (Stafford & Singer, 1998).  This is probably due to the 
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increase in treated AF.  Warfarin, although effective, is at times difficult to manage due 
to the narrow therapeutic range.  This range is defined by the International Normalized 
Ratio (INR).  The typical therapeutic range for INR in patients being treated to prevent 
thrombosis is 2.0-3.0.  The INR is a calculation that uses the prothrombin time (PT) 
blood test.  Prothrombin time measures the clotting mechanism of the extrinsic 
coagulation system.   The coaglulation cascade is dependent on coagulation factors 
produced in the liver and dependent on vitamin K formation.  VKAs such as warfarin, 
delay the formation of vitamin K which prolong the PT.  Significant changes in the INR 
(<2.0 or >3.0) can increase morbidity and mortality.   The consequences of 
subtherapeutic anticoagulation include thrombus formation which can result in embolism 
and death.  Supratherapeutic anticoagulation can result in hemorrhages that can also 
be life threatening.  Hylek et al. (2003) found a 1.9 fold increased risk of stroke in AF 
patients with an INR of 1.9.   
 In addition to INR, clotting can be tested by measuring D-dimer, activated partial 
thromboplastin time (aPTT), activated protein C resistance (APC-R) and von Willebrand 
factor activity (RCo)  in blood.  D-dimer is produced by the action of plasmin on cross-
linked fibrin.  D-dimer is not produced when plasmin acts on fibrinogen not involved in 
clot formation.  Thus, the presence of D-dimer confirms the activation of fibrinolysis, 
secondary to thrombin generation.  Clot degradation can also be tested.  One method is 
by measuring plasminogen activator inhibitor 1 (PAI-1), which decreases fibrinolysis.  
An increase in PAI-1 shows a decrease in breakdown of clot material leading to an 
imbalance in hemostasis.  The intrinsic coagulation system can be tested with aPTT.   
Increases in APC-R show increased resistance to activated protein C which inactivates 
8 
 
procoagulant factors and increases risk for venous thromboembolic disease.  Other 
tests examined by studies in this review are beta thromboglobin (BTG) and platelet 
factor 4 (PF4), which indicate platelet activation. 
Purpose of the Study 
 The purpose of this paper is to perform a systematic review of the current 
literature regarding the affect of altitude on coagulation parameters.  The results can 
then be applied to patients using warfarin therapy to prevent thromboembolic events 
when traveling to higher altitudes.  The Grading of Recommendations, Assessment, 
Development, and Evaluation (GRADE) tool will be used to evaluate the body of 
evidence (Guyatt, 2008).   
METHODS 
An extensive literature search was performed using PubMed, Medline, Web of 
Science, Cochrane Systematic Reviews, Evidence Based Medicine Reviews Multifile 
and CINHAL. These databases were accessed through the Pacific University Library 
system. The keywords searched were: Altitude, Coagulation, Anticoagulation, Warfarin, 
International Normalized Ratio, Hypobaric, Hypoxia, individually and in combination. 
The search was limited to human subjects.   Articles published before 1989 were 
excluded. The initial search resulted in 24 articles.  Subsequently, duplicate articles, 
traditional reviews and studies that focused on special populations other than warfarin 
patients and high altitude, were excluded.  This resulted in ten studies, three of which 
were used in this review.  The three studies used were chosen by the final inclusion 
criterion which was extended exposure to higher altitudes. 
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RESULTS 
Risk of Impaired Coagulation in Warfarin Patients Ascending to Altitude (>2400m). 
Tissot van Patot et al. (2006) investigated the factors associated with travel, to 
and from, altitudes that lead to a decrease or increase of INR values in patients using 
warfarin.  The study was a retrospective review of medical charts of warfarin patients in 
a cardiology clinic located in Colorado at an altitude of 2400m.  A total of 1139 INR 
measurements from 49 patients between August 1998 and October 2003 were used. 
Inclusion criteria for subjects were: current warfarin therapy and residency at the same 
location.  The authors recorded the following chronic conditions or diseases: atrial 
fibrillation, hypertension, hyperlipidemia, valve replacement and cardiomyopathy.  
Travel was defined as descent from altitude and ascent back to home altitude.  Low 
altitudes were between sea level and 1500m.  When residents descended to lower 
altitudes, INR measurements were taken in clinics and results were faxed to the 
cardiology clinic.  Travel period was defined as 60 days prior to travel (pre travel INR) 
and 14 days post travel (post travel INR).  Inclusion criteria for INR measurements 
were: at least one travel associated INR measurement; up to five pretravel 
measurements per subject; initial post travel INR measurement.  INR measurements 
were excluded if: pretravel measurement was taken less than 21 days after previous 
travel period; warfarin dosage was missed during travel period; warfarin dosage was 
changed during travel period; PT was considered unstable prior to travel period. 
According to Tissot van Patot et al. (2006), warfarin patients without atrial 
fibrillation had a 2.7 fold risk of having a subtherapeutic INR after traveling to an altitude 
of 2400m (95% CI= 1.2-5.8); warfarin patients with atrial fibrillation had a 2.1 fold risk of 
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subtherapeutic INR at an altitude of 2400m (95% CI= 1.4-3.2); warfarin patients with 
atrial fibrillation and travel to an altitude of 2400m, had a 5.6 fold risk of subtherapeutic 
INR.  The median reduction of INR with ascent to an altitude of 2400m after being at 
sea level for an extended amount of time, was -.56 (range= -1.3 to -.10) in patients with 
atrial fibrillation and -.70 (range= -1.7 to -.50) in patients without atrial fibrillation.  The 
authors concluded that warfarin patients ascending to altitudes of 2400m or more, have 
an increased risk of subtherapeutic INR levels and should be subject to more closely 
monitored INRs. 
Changes of Coagulation Parameters During High Altitude Expedition 
A study conducted by Pichler-Hefti et al. (2010) was conducted from June 14- 
July 8, 2005 on Mount Muztagh Ata (7537m).  This observational study investigated the 
effect of altitude on hemostatic parameters.  Thirty four mountaineers, all lowland 
residents, were randomly placed in two groups.  A different acclimatization schedule 
was given to each group.  One group climbed with a faster ascent and less 
acclimatization time (9 days acclimatizing at altitudes between 3750m- 5533m).  The 
second group spent 13 days acclimatizing between 3750m – 5533m.  Base camp for 
both groups was at 4497m. All subjects spent two nights at 5533m, two nights at 6265m 
and one night at 6865m.  Medical tests were performed at base camp and the three 
upper camps by 15 researchers who were not members of the subject groups.  
Inclusion criteria were: previous trekking experience and experience with 
sojourns at altitude.  Subjects with prior experience of severe acute mountain sickness 
(AMS) or high altitude pulmonary edema (HAPE) were not excluded.  Exclusion criteria 
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were:  evidence of cardiac or respiratory disease and regular use of medications.  
Subjects were allowed to use analgesics (paracetamol, aspirin, ibuprofen, mefenaminic 
acid) as needed.  Medication use was entered in a log book.  While these medications 
interfere with platelet function, Pichler-Hefti et al. (2010) reported, “We did not expect 
interaction of the medication used with the study results because endothelial and 
coagulation factor activation rather than platelet activation was the subject of our 
research” (Pichler-Hefti et al., p.112).   
The hemostatic parameters tested were PT, activated partial thromboplastin time 
(aPTT), D-dimer, activated protein C resistance (APC-R), von Willebrand factor activity 
(RCo), ADAMTS-13 and C-Natriuretic Peptide (CNP).  Acute mountain sickness was 
assessed using the Lake Louise AMS score. 
Pichler-Hefti et al. (2010) reported that D-dimer values gradually increased with 
altitude.  PT increased with altitude indicating procoagulant changes and protein C 
inactivation.  APC-R decreased and aPTT showed a significant increase.  Von 
Willebrand factor RCo decreased.  No significant changes were found in ADAMTS-13 
and CNP.  Secondary findings showed no relationship between AMS scores and 
coagulation parameters.  Additional secondary findings showed a higher RCo and a 
lower ADAMTS-13 in the faster ascent group.  The authors concluded that ascending to 
higher altitude activates coagulation and enhances procoagulatory state and could 
increase risk of a thrombotic episode.  
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High Altitude: A Hypercoagulable State: Results of a Prospective Cohort Study 
 A prospective cohort study was performed in 2002 on Indian soldiers deployed to 
high altitudes (Kotwal, 2007).  Thirty eight subjects were randomly chosen to take part 
in the study.  All subjects had normal physical exams before induction and no 
comorbidities or coagulation disorders were found.  Tests were performed at enrollment, 
3 months, and 8 months.  Baseline studies were compared to a matched group who 
remained at low altitude.  Tests were conducted at 3500m. Thirty two subjects were 
followed for the full eight months. 
 The inclusion criterion was:  healthy soldiers age 20-40.  The exclusion criteria 
were:  comorbidities such as obesity, hypertension, and biochemical abnormalities.  The 
following tests were done at enrollment, 3 months, and 8 months: hemoglobin, platelet 
count, fibrinogen, BTG, PF4, plasminogen activator inhibitor 1 (PAI-1), protein C, protein 
S, antithrombin III, APC-R, Bleeding time (BT), Clotting time (CT), aPTT, PT and D-
dimer.  
 The authors reported an increase in hemoglobin, platelet count, fibrinogen, BTG, 
PF4, and PAI-1.  No significant changes were found in protein C, protein S, BT, CT, 
APC-R, PT, aPTT and D-dimer.  The authors reported that the combination of increased 
hemoglobin from erythrocytosis, increased platelet count, increased fibrinogen and 
increased PAI-1, causes an imbalance in hemostasis and increases risk of thrombotic 
events.  Kotwal et al. (2007) concluded that extended stay at high altitude causes a 
hypercoagulable state.   
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DISCUSSION 
The intent of this review was to examine the effect of ascending to higher 
elevations on coagulation factors.  The initial literature search was directed at finding 
studies which evaluated the effects of long term increase in altitude on INR of 
warfarinized patients.   Only one study was found which examined effect of increased 
altitude on INR of warfarinized patients.  However, a substantial number of studies were 
found that focused on the effect of increased altitude on coagulation.  A selected 
number of those studies were used in this review.  Articles were chosen based on study 
of INR, extended stay of subjects at higher altitude, detailed description of methodology 
by the authors and high quality of the individual studies.  Articles were excluded if they 
examined effect of altitude during airline flights or in laboratory built hypobaric 
chambers.  
Grading the Evidence 
 Each common outcome in the studies reviewed was evaluated using GRADE.  
GRADE is a tool used to standardize the analysis and evaluate the quality of the data.  
GRADE ranks the evidence as very low, low, moderate or high (Guyatt et al., 2008).  
According to the GRADE Working Group, definitions of the GRADE ranks are as 
follows:  
High- further research is very unlikely to change confidence in the estimate of 
effect; Moderate- further research is likely to have an important impact on our 
confidence in the estimate of effect and may change the estimate; Low- further 
research is very likely to have an important impact on our confidence in the 
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estimate of effect and is likely to change the estimate; Very low- any estimate of 
effect is very uncertain (Guyatt et al., 2008, p. 926).  
  All three outcomes used in this review had an initial rating of low based on a 
study design of observational.  Only randomized controlled trials carry an initial rating of 
high, all other study types are given a low rating within the GRADE guidelines.  Based 
on GRADE guidelines, an outcome grade can increase or decrease based on specific 
study parameters.  Parameters that decrease high and moderate outcomes are study 
limitations, inconsistency, indirectness, imprecision and reporting bias (Guyatt et al., 
2008).  Parameters that can increase low or moderate quality of evidence are large 
magnitude of effect, dose-response relationship and control of confounders (Guyatt et 
al., 2008).   The GRADE table examines the quality of evidence based on changes in 
coagulation parameters with an increase in altitude (Appendix, Table1).  Each study 
showed a positive association with the outcome but the overall quality of evidence was 
rated low based on study design and absence of parameters that could have increased 
the GRADE rating. 
Study Limitations 
 Several common limitations were present in each study.  The first was small 
samples sizes.  In the Tissot van Patot et al. (2006) study, there were 1139 INR 
measurements used, which is a significant number, but it came from 39 individuals.   
Even though these subjects were ideal candidates for the study, and for this systematic 
review, the study quality would have increased had they studied a larger population.  
The Pichler-Hefti et al. (2010) study had 34 subjects and suffered from the same 
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limitation.  Overall, this observational study was executed with integrity and consistency.  
Likewise, the cohort study by Kotwal et al. (2006) suffered from the same limitation.  
Even though the results of these studies were statistically significant, larger sample 
sizes would have increased the GRADE rating.  Replication of these studies with larger 
study groups would be difficult based on location. 
 Another common limitation of each study was failure to factor in diet as an effect 
on coagulation.  It should be mentioned that during travel and mountain expeditions, an 
individual’s intake of vitamin K can change due to a variation in diet.  Deficiency in 
vitamin K can affect coagulation factors that are produced in the liver.   
 Two of the studies shared limitations that were not present in the third.  The 
Pichler-Hefti et al. (2010) and Kotwal et al. (2006) used non-warfarinized subjects.  
Despite this, these studies were relevant to this systematic review due to their study of 
the effect of altitude on coagulation parameters.  These studies were quality studies that 
showed altitude as a risk factor for hypercoagulation.   
 Another limitation of all three studies is that they failed to incorporate detailed 
data regarding the subjects’ use of over the counter medications like aspirin and 
NSAIDS, which have anticoagulant properties.  Even with this limitation, every study 
was able to demonstrate how altitude increases risk for hypercoagulation.   
Conclusions 
 This systematic review reveals an increased risk of hypercoagulability at high 
altitudes.  This hypercoagulability can have a negative effect on INR and therefore, an 
increase in altitude could increase the risk of a subtherapeutic INR.  Clinicians who 
16 
 
have patients taking warfarin who are traveling to higher altitudes or clinicians working 
at higher altitudes whose warfarinized patients travel to lower elevations to escape the 
cold weather and return to higher altitudes with the warmer seasons may benefit from 
this review.  It is suggested that clinicians caring for warfarinized patients, monitor INR 
more closely when their patients travel to higher altitudes.   Furthermore, any patient 
using medications that may affect their coagulation parameters should be monitored 
more closely when spending time at higher altitudes. 
There is not enough evidence or data to recommend a change of warfarin 
dosage in anticipation of a decrease in INR that could increase risk of thrombotic 
events.  Future studies should be performed considering this clinical dilemma.  Larger 
subject groups along with a greater number of INR measurements will yield better 
results.   A range of increase in altitude could be examined to provide more precise 
changes in coagulation parameters, and length of stay at a variety of altitudes should be 
further investigated.  Use of other interventions besides warfarin may become 
important. Future studies should also address diet and measure coagulation factors at 
baseline.  Baseline should be described as being at home with a consistent diet. 
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Table 2. Kotwal et al. study results. 
 
 
 
 
 
 
 
 
 
 
 
Table 2.  Kotwal et al. study.   Significant mean values of tests performed on 
subjects at induction to altitude;  3 months and 8 months at altitude. 
TESTS INDUCTION TO 
ALTITUDE 
3 MONTHS AT 
ALTITUDE 
8 MONTHS AT 
ALTITUDE 
Hemoglobin 14.0 15.7 16.6 
Platelet count 254 306 342 
BTG 29.8 38.7 47.5 
PF4 3.9 7.6 13.9 
PAI-1 23.7 40.1 49.3 
Fibrinogen 253 304 346 
21 
 
Table 3. Tissot van Patot et al. study results. 
Table 3.  Tissot van Patot et al. study.  Increased 
risk of Subtherapeutic INR 
Risk Factor Odds Ratio with 95% CI 
Atrial Fibrillation 2.1 
Ascent to Altitude 2.7 
Ascent to Altitude 
with Atrial Fibrillation 
5.6 
Above values are compared to warfarin patient without 
atrial fibrillation and without ascent to altitude. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
